Profound Medical Corp.

NASDAQ:PROF

Medical - Devices

Healthcare
$6.91 +4.11%

+$0.27 today

Market cap
$253.09M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $3.76High $8.95

Volume 0.08M

Average 0.12M

PROF Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Profound Medical Corp.NASDAQ: PROF

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $1.48M rose 93.8% year over year, ahead of the +17.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 26.4% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Cost of revenue amounted to 29.2% of revenue in FY2025, down 4.9 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +93.8% holds above the trailing-twelve-month pace of +17.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.48M-26.4% QoQ
Last fiscal yearDec 2025
$4.79M+38.0% YoY
LTMMar 2026
$5.46M+17.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.8%——
1 year+38.0%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
4.79M USD
Year-over-year change
+38.0%
4-year CAGR
+5.1%

Cost of Revenue vs competitors

How PROF compares with its peers on the latest reported figures

  • PROF's LTM Mar 2026 cost of revenue of $5.46M is the 8th highest of the 11 companies compared; the peer median is $16.25M.
  • Its year-over-year change of +17.1% is the 6th highest of 10, against a peer median of +17.4%.
  • Cost of revenue amounts to 28.9% of revenue for PROF, versus a peer median of 50.6%.
PROF Competitors Peer median
Cost of Revenue for PROF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STIMNeuronetics, Inc.LTM Mar 2026$78.91M +141.8%+70.6%52.0%
OWLTOwlet, Inc.LTM Mar 2026$52.61M +30.6%+4.4%49.1%
PREPrenetics Global LimitedLTM Mar 2026$47.41M +110.1%+65.9%41.7%
LNSRLENSAR, Inc.LTM Mar 2026$31.55M +5.2%+26.7%54.7%
NNOXNano-X Imaging Ltd.LTM Dec 2025$25.81M +17.4%+18.6%198.2%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$6.7M +44.8%+45.6%14.9%
MXCTMaxCyte, Inc.LTM Mar 2026$6.23M -13.4%+6.9%19.3%
PROFProfound Medical Corp.LTM Mar 2026$5.46M +17.1%+9.4%28.9%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$2.63M ——426.2%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.33M +13.5%-8.4%71.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$823K -40.6%-64.8%27.8%
Peer median (excluding PROF) $16.25M+17.4%+18.6%50.6%

Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.17M16.38M
Cost of Revenue3.92M3.66M2.82M3.47M4.79M
Gross Profit2.95M3.02M4.38M6.7M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.15M20.96M
Selling, General & Admin17.97M17.93M18.62M22.02M32.61M
Operating Expenses33.24M35.15M33M38.17M53.57M
Depreciation & Amortization1.88M1.6M1.15M891.06K569.8K
EBITDA(28.65M)(26.6M)(26.78M)(25.59M)(41.41M)
EBITDA Margin-416.8%-398.2%-372.0%-251.7%-252.8%
Operating Income(30.29M)(32.13M)(28.62M)(31.47M)(41.98M)
Operating Margin-440.7%-480.9%-397.5%-309.6%-256.3%
Interest Income203.2K1.05M1.64M1.37M1.09M
Interest Expense66.41K167.11K770K00
Other Income / Expenses(303K)3.74M(81K)4.99M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(26.48M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(1.9K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(26.48M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.07)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.07)(1.43)
Weighted Avg Shares20.46M20.83M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.83M21.18M24.77M30.23M

Profound Medical Corp.

NASDAQ:PROF

Intrinsic Alpha fair value

Locked

Current Price

$6.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.